Perrigo Co. (NasdaqGS:PRGO) acquired Rosemont Pharmaceuticals Limited from CBPE Capital LLP and management of Rosemont for approximately $280 million in cash on February 11, 2013. Under the terms of agreement, 200 employees of Rosemont will join Perrigo. For the year ending 2012, Rosemont reported net sale of £40 million ($64.61 million). The acquisition is anticipated to be approximately $0.24 accretive to adjusted EPS and approximately neutral to GAAP EPS in its first ... 12 months post-closing and accretive to ROIC in fiscal year 2015. Rothschild acted as financial advisor, Nigel Ward, Joel Smith, Gordon Singer, Graeme Hurst, Mark Wilson, Oliver Dunn and Nicola Widdison of PricewaterhouseCoopers acted as financial advisor to Rosemont Pharmaceuticals Ltd and L.E.K Consulting acted as consultant for CBPE. Andy Stylianou, Graham Spalding, Victoria Hirst and Patrick Allan of Wragge & Co. acted as legal advisor for CBPE Capital LLP and management of Rosemont. CMS Cameron McKenna acted as legal advisor for Perrigo. Peter Ogden of Maitland acted as public relations advisor for CBPE. The conversions for financials were made through www.oanda.com on December 31, 2012.
Read More

Perrigo Co. (NasdaqGS:PRGO) signed a definitive agreement to acquire Velcera Inc. (OTCPK:VLCR) for $160 million on February 1, 2013. The transaction is subject to satisfaction of closing conditions, including regulatory approvals and is expected to close within the year 2013. The transaction is accretive by $0.11 adjusted EPS for Perrigo for financial year 2014 and is expected to be ROIC accretive in fiscal 2015. Greg Astrachan of Willkie Farr & Gallagher LLP acted as ... the legal advisor for Velcera Inc. Sheryl Orr, Robert Robison, Priscila McCalley, Sarah Grimm, Gary Rothstein, Eric Sarabia, Scott Stempel, Harry Robins, David Brenneman, Kenneth Kail, Kathleen Martin, Rebecca Roman and Judith Walkoff of Morgan, Lewis & Bockius LLP acted as the legal advisor for Perrigo Co. J.P. Morgan Securities Inc. acted as financial advisor to Velcera. Cravath, Swaine & Moore LLP acted as legal advisor to J.P. Morgan Securities Inc.
Read More

Perrigo Co. (NasdaqGS:PRGO) acquired remaining 81.5% stake in Cobrek Pharmaceuticals, Inc. from Pentech Pharmaceuticals, Inc. and others for approximately $45 million in cash on December 28, 2012. The deal value of $45 million is on a cash free and debt free basis. As part of the transaction, Cobrek will forgo any profit share payments earned during Perrigo's fiscal second quarter 2013. Acquisition and consolidation is anticipated to be approximately $0.01 accretive ... to GAAP and $0.04 accretive to adjusted earnings per share in fiscal year 2013 and immediately accretive to ROIC hurdles.
Read More

Sponsored Financial Commentaries

To contact PERRIGO CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.